These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 25307964

  • 41. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 42. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Jul 18; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 43. Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
    Wahidiyat PA, Yosia M, Sari TT.
    Acta Med Indones; 2018 Apr 18; 50(2):168-176. PubMed ID: 29950538
    [Abstract] [Full Text] [Related]

  • 44. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Apr 18; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 45. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Apr 18; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 46. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Br J Haematol; 2009 Apr 18; 145(2):245-54. PubMed ID: 19236376
    [Abstract] [Full Text] [Related]

  • 47. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
    Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Di Maggio R, Calvaruso G, Pantalone GR, Rigano P.
    Am J Hematol; 2012 Jul 18; 87(7):732-3. PubMed ID: 22622672
    [Abstract] [Full Text] [Related]

  • 48. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Jul 18; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 49. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 18; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 50. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct 18; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 51. How I treat transfusional iron overload.
    Hoffbrand AV, Taher A, Cappellini MD.
    Blood; 2012 Nov 01; 120(18):3657-69. PubMed ID: 22919029
    [Abstract] [Full Text] [Related]

  • 52. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun 01; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 53. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
    Filosa A, Vitrano A, Rigano P, Calvaruso G, Barone R, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Casale M, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Maggio A.
    Blood Cells Mol Dis; 2013 Aug 01; 51(2):85-8. PubMed ID: 23628348
    [Abstract] [Full Text] [Related]

  • 54. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 01; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 55. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct 01; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 56. Deferiprone.
    Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F.
    Ann N Y Acad Sci; 2010 Aug 01; 1202():75-8. PubMed ID: 20712776
    [Abstract] [Full Text] [Related]

  • 57. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 58. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Feb 15; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 59. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ.
    Hemoglobin; 2006 Feb 15; 30(2):329-47. PubMed ID: 16798657
    [Abstract] [Full Text] [Related]

  • 60. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
    Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G.
    Br J Haematol; 2006 Aug 15; 134(4):438-44. PubMed ID: 16822284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.